Literature DB >> 18756069

Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

Heekyoung Choi1, Su Jin Jeong, Han Sung Lee, Bum Sik Chin, Suk Hoon Choi, Sang Hoon Han, Myung Soo Kim, Chang Oh Kim, Jun Yong Choi, Young Goo Song, June Myung Kim.   

Abstract

The combination of atazanavir (ATV) and lopinavir/ritonavir (LPV/RTV) with nucleoside reverse transcriptase inhibitors (NRTI) has been used as a salvage regimen for human immunodeficiency virus (HIV)-positive patients. In this paper, we discuss two cases of HIV-positive patients who had long histories of virological failure following a heavy treatment of antiretroviral drugs, but then achieved virological suppression with double-boosted protease inhibitor (PI) regimens. In patients with multiple genotypic resistance to PIs and NRTIs, virological suppression can be achieved with a combination of ATV plus LPV/RTV with an NRTI backbone. The two cases in this report suggest that a combination of ATV plus LPV/RTV could be a useful salvage regimen for the subset of HIV-positive patients with limited treatment options.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756069      PMCID: PMC2526394          DOI: 10.3346/jkms.2008.23.4.737

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  17 in total

Review 1.  Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.

Authors:  Zelalem Temesgen; Francesca Cainelli; Eric M Poeschla; Stacey A R Vlahakis; Sandro Vento
Journal:  Lancet Infect Dis       Date:  2006-08       Impact factor: 25.071

2.  Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

Authors:  Angela Dm Kashuba; Camlin Tierney; Gerald F Downey; Edward P Acosta; Emanuel N Vergis; Karin Klingman; John W Mellors; Susan H Eshleman; Trevor R Scott; Ann C Collier
Journal:  AIDS       Date:  2005-01-28       Impact factor: 4.177

3.  Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Authors:  Esteban Ribera; Rosa M Lopez; Marjorie Diaz; Leonor Pou; Lidia Ruiz; Vicenç Falcó; Manuel Crespo; Carlos Azuaje; Isabel Ruiz; Imma Ocaña; Bonaventura Clotet; Albert Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

5.  The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.

Authors:  Schlomo Staszewski; Errol Babacan; Christoph Stephan; Annette Haberl; Amina Carlebach; Peter Gute; Stephan Klauke; Yvonne Hermschulte; Martin Stuermer; Brenda Dauer
Journal:  J Antimicrob Chemother       Date:  2006-09-06       Impact factor: 5.790

6.  Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

Authors:  Esteban Ribera; Carlos Azuaje; Rosa M Lopez; Marjorie Diaz; Maria Feijoo; Leonor Pou; Manuel Crespo; Adria Curran; Imma Ocaña; Albert Pahissa
Journal:  AIDS       Date:  2006-05-12       Impact factor: 4.177

Review 7.  Protease-inhibitor boosting in the treatment-experienced patient.

Authors:  Joel E Gallant
Journal:  AIDS Rev       Date:  2004 Oct-Dec       Impact factor: 2.500

Review 8.  The pharmacokinetics of HIV protease inhibitor combinations.

Authors:  Marta Boffito; Desmond Maitland; Yohan Samarasinghe; Anton Pozniak
Journal:  Curr Opin Infect Dis       Date:  2005-02       Impact factor: 4.915

9.  Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

Authors:  Andrea De Luca; Francesco Baldini; Antonella Cingolani; Simona Di Giambenedetto; Richard M Hoetelmans; Roberto Cauda
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-01       Impact factor: 3.731

10.  Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

Authors:  Christoph Stephan; Nils von Hentig; Irene Kourbeti; Brenda Dauer; Manfred Mösch; Thomas Lutz; Stephan Klauke; Sebastian Harder; Michael Kurowski; Schlomo Staszewski
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

View more
  4 in total

1.  Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.

Authors:  Pyoeng Gyun Choe; Wan Beom Park; Jin Su Song; Nak-Hyun Kim; Kyoung-Ho Song; Sang Won Park; Hong Bin Kim; Nam Joong Kim; Myoung-don Oh
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

2.  Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

Authors:  Omar Janneh; Patrick G Bray; Elizabeth Jones; Christoph Wyen; Peter Chiba; David J Back; Saye H Khoo
Journal:  J Antimicrob Chemother       Date:  2010-03-17       Impact factor: 5.790

3.  Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients.

Authors:  Dhakshinamoorthy Subashini; Thongadi Ramesh Dinesha; Jayaseelan Boobalan; Lawrence Christopher Samuel; Selvamuthu Poongulali; Ambrose Pradeep; Sunil Suhas Solomon; Suniti Solomon; Pachamuthu Balakrishnan; Shanmugam Saravanan
Journal:  Indian J Pharmacol       Date:  2016 Sep-Oct       Impact factor: 1.200

4.  Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure.

Authors:  Bum Sik Chin; Ju-Yeon Choi; Jin Young Choi; Gab Jung Kim; Mee-Kyung Kee; June Myung Kim; Sung Soon Kim
Journal:  J Korean Med Sci       Date:  2009-11-07       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.